Powerdyne International Inc (PWDY): I had so much high hopes for this. Anoth...

LonesomeGeorge · 2025-02-03T21:16:47.6930000Z

I had so much high hopes for this. Another bust.

Play Episode

6min

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

Chesnara CEO discusses strong 2024 results, dividend growth and M&A outlook

Chesnara PLC (LSE:CSN) CEO Steve Murray talked to Proactive's Stephen Gunnion about the company’s strong 2024 full-year results, highlighting robust cash generation and consistent dividend growth. Murray highlighted that Chesnara generated £60 million in cash over the year, providing strong dividend coverage and supporting its 20-year track record of uninterrupted dividend growth. The business also increased its overall value and maintained a strong solvency position. The interview also covered Chesnara’s acquisition strategy, with Murray detailing the second Canada Life deal, which delivered an uplift in economic value to £11 million—higher than the £8 million initially expected—off a £2 million consideration. He explained that Chesnara currently holds around £200 million in acquisition firepower, supported by a solvency capital ratio of 203%. Murray described the current M&A pipeline as “positive,” noting that a reduction in private equity competition is opening up new opportunities in the UK and Benelux. He also commented on broader macroeconomic conditions, noting that despite some volatility, Chesnara’s long-term outlook remains stable due to natural hedges and long-duration contracts. Looking ahead to 2025, Murray reiterated Chesnara’s confidence in maintaining dividend growth, underpinned by strong visibility on future cash flows well above required commitments. For more CEO interviews and investor insights, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and hit the notification bell so you never miss an update. #Chesnara #InsuranceStocks #DividendGrowth #MergersAndAcquisitions #CashGeneration #UKStocks #BeneluxMarkets #CanadaLifeDeal #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

CleanSpace eyes 30% growth, EBITDA breakeven

CleanSpace Holdings Ltd CEO Gabrielle O’Carroll talked with Proactive about AIM's Small and Midcap Conference about the company’s growth trajectory and product innovation in powered air purifying respirators (PAPRs). CleanSpace was founded in 2009, based on an innovation developed during the SARS epidemic. The company's differentiator is its lightweight, head-mounted respirators that contrast with the bulkier waist-mounted models commonly available in the industrial market. “We are steadily approaching that breakeven EBITDA, profitable EBITDA position, which is our goal,” O’Carroll said. O’Carroll explained that CleanSpace's respirators are well suited for industrial sectors like mining, infrastructure, and petrochemicals. The products are marketed in key regions including the United States, Western Europe, and Australia. The company has 52 employees and recorded AU$9.2 million in revenue in the first half, up 26% year-over-year. CleanSpace is targeting annual revenue growth of 25–30% and expects to achieve positive EBITDA soon. To drive this, the company is focused on raising brand awareness, engaging directly with end users, and supporting occupational hygienists and safety managers. CleanSpace is also investing in R&D to support future product launches. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #CleanSpaceHoldings #IndustrialSafety #RespiratoryProtection #PAPR #WorkplaceSafety #OccupationalHealth #ASXStocks #HealthTech #EBITDA #MiningSafety #InfrastructureSafety #ProactiveInvestors

Followers	14
Posts	948
Boards Moderated	0
Alias Born	07/09/2015

Volume:	980,854
Day Range:	0.0009 - 0.0011
Bid:	0.0009
Ask:	0.0011
Last Trade Time:	12:24:39 PM EDT
Total Trades:	6

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

PWDY Detailed Quote

Recent PWDY News

More PWDY News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent PWDY News

Go Ad-Free